Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003818 | 0.90 | ACLY (0.53) | TP53LMNAALOX15TSHRPOLB | |
| SCHEMBL13114307 | 0.89 | POLB (0.52) | TP53LMNAALOX15TSHRPOLB | |
| SCHEMBL14115042 | 0.87 | PTGS2 (0.50) | TP53LMNAALOX15TSHRPOLB | |
| SCHEMBL13114473 | 0.87 | KDM4E (0.59) | TP53LMNAALOX15TSHRKMT2A | |
| SCHEMBL3456294 | 0.80 | CNR1 (0.60) | LMNAPOLBCNR1KMT2AALDH1A1 | |
| SCHEMBL1807927 | 0.80 | EPHX2 (0.47) | TP53CNR1HRH3HRH1 | |
| SCHEMBL15651541 | 0.79 | LRRK2 (0.50) | TP53LMNAALOX15TSHRPOLB | |
| SCHEMBL9572754 | 0.78 | KCNH2 (0.59) | LMNAPOLBKMT2AALDH1A1RXFP1 | |
| SCHEMBL8355113 | 0.78 | KMT2A (0.63) | TP53TSHRPOLBKMT2AALDH1A1 | |
| SCHEMBL13114466 | 0.77 | KDM4E (0.64) | LMNAPOLBKMT2AALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | TP53 4367/4885LMNA 4391/4885ALOX15 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.